SRNE - Sorrento Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.6000
+0.0200 (+0.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5800
Open2.5600
Bid2.5800 x 1000
Ask2.6200 x 2200
Day's Range2.5050 - 2.6489
52 Week Range1.8000 - 6.5000
Volume1,225,107
Avg. Volume1,173,201
Market Cap318.846M
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-2.4170
Earnings DateMay 23, 2019 - May 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.00
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants

    SAN DIEGO, July 02, 2019 -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to.

  • Implied Volatility Surging for Sorrento (SRNE) Stock Options
    Zacks20 days ago

    Implied Volatility Surging for Sorrento (SRNE) Stock Options

    Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

  • Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today
    Motley Fool23 days ago

    Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today

    Find out which bad news sent these stocks lower.

  • Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering
    InvestorPlace23 days ago

    Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering

    Sorrento Therapeutics news for Friday concerning a new equity offering has SRNE stock falling hard.Source: Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) notes that it will be making a public offering of its common stock. It will also be offering Series A, Series B and Series C warrants to purchase shares of its common stock. The company will be selling these shares an accompany warrants for $3.00 each.The Sorrento Therapeutics news release notes that the company is planning to use funds from this public offering for a variety of purposes. This includes "continued clinical development of its RTX, CEA CAR-T and CD38 CAR-T programs and general research and development, working capital and general corporate purposes."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe public offering from Sorrento Therapeutics includes 8,333,334 shares of SRNE stock and Series A, Series B and Series C warrants to purchase an aggregate of 8,333,334 shares of SRNE stock. Underwriters of the offer will also have the option of purchasing an additional 15% of shares and or warrants in the public offering.The Sorrento Therapeutics news also includes the restrictions on the warrants. This includes the Series A warrants being exercisable six months after purchase for a price of $3.75 and expire after 10 years. * The 7 Top Small-Cap Stocks Of 2019 As for the Class B warrants, they are exercisable at the time of issuance for $3.00 and expire nine months after that date. The Class C warrants are exercisable after purchase for $3.75 and expire after 10 years. This warrants also require that the corresponding Class B warrant be exercised.The public offering is expected to last through July 2.SRNE stock was down 18% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Top Small-Cap Stocks Of 2019 * Critical Levels to Watch in 7 Marijuana Stocks * 5 Smaller Cloud Stocks That Have Plenty of Potential As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering appeared first on InvestorPlace.

  • GlobeNewswire23 days ago

    Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

    Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the pricing of its public offering of 8,333,334 shares of its common stock, Series A warrants to purchase up to an aggregate of 8,333,334 shares of its common stock, Series B warrants to purchase up to an aggregate of 8,333,334 shares of its common stock and Series C warrants to purchase up to an aggregate of 8,333,334 shares of its common stock, at a price to the public of $3.00 per share and accompanying Series A, Series B and Series C warrant. The Series A warrants will be exercisable commencing six months from the date of issuance, will expire on the 10-year anniversary of the date of issuance and will have an exercise price of $3.75 per share, subject to certain adjustments.

  • GlobeNewswire23 days ago

    Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

    Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series A, Series B and Series C warrants to purchase shares of its common stock in an underwritten public offering. Sorrento also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrant combinations, which consist of Series A, Series B and Series C warrants, offered in the public offering on the same terms and conditions.

  • Benzingalast month

    Sorrento Therapeutics Shares Move On RTX Trial Update

    Sorrento Therapeutics Inc (NASDAQ: SRNE ) announced Wednesday that the Phase 1b study of its drug resinferatoxin is in progress and has generated positive data.  The RTX drug has the potential to be on ...

  • GlobeNewswirelast month

    Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy 

    “CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic.

  • GlobeNewswirelast month

    Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

    Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group). Most adverse events associated with RTX administration were expected and included pain, hypertension and tachycardia.

  • GlobeNewswirelast month

    Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

    SAN DIEGO, June 14, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences.

  • GlobeNewswirelast month

    Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company

    Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding Company. No decisions have been taken at this point on the structure or timing of any initial public offering, and no assurance can be given that an initial public offering will be pursued or completed. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

  • GlobeNewswirelast month

    Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a local nerve block injection for the control of neuropathic post-amputation residual limb pain in humans. The population of “aging amputee cats” living with the sequalae of surgeries performed years ago is quite large making it a valuable “model” when looking at residual limb pain which affects about 30% of the 1.6 million American amputees, or phantom limb pain which affects up to 70% of those human patients1.

  • GlobeNewswire2 months ago

    Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration

    Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (SRNE), announces the completion of post-merger integration. Following the merger with Semnur Pharmaceuticals, Inc. in March 2019, and the contribution of Scilex Pharmaceuticals Inc. equity to Scilex Holding Company, Scilex rapidly proceeded to implement key changes necessary to ensure the long-term success of the newly formed company. Gross sales in the past three months have shown strong and sustained month-over-month growth, increasing from approximately $1 million in March, to $2.4 million in April and $3.3 million in May, respectively.

  • GlobeNewswire2 months ago

    Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships

    SAN DIEGO, June 04, 2019 -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd..

  • Why Sorrento Therapeutics Is Getting Crushed Today
    Motley Fool2 months ago

    Why Sorrento Therapeutics Is Getting Crushed Today

    The biopharma stock is continuing to experience volatility today.

  • GlobeNewswire2 months ago

    Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).

    SAN DIEGO, May 21, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB.

  • Options Traders Expect Huge Moves in Sorrento (SRNE) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Sorrento (SRNE) Stock

    Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

  • What's in Store for Sorrento (SRNE) This Earnings Season?
    Zacks3 months ago

    What's in Store for Sorrento (SRNE) This Earnings Season?

    Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

  • ACCESSWIRE3 months ago

    Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc.

    HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...

  • GlobeNewswire3 months ago

    Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions.

  • Why Sorrento Therapeutics Is Jumping Today
    Motley Fool3 months ago

    Why Sorrento Therapeutics Is Jumping Today

    Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.

  • GlobeNewswire3 months ago

    Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study aimed at exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory processes associated with Parkinson’s disease in a rodent model. Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. Transient receptor potential vanilloid 1 (TRPV1) is involved in pain perception and is highly expressed in sensory neurons.

  • Here's Why Sorrento Therapeutics Soared 134% in March
    Motley Fool3 months ago

    Here's Why Sorrento Therapeutics Soared 134% in March

    The early-stage biotech jumped without any significant news.

  • Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme
    American City Business Journals4 months ago

    Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme

    Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.